随着5G 的逐步大规模建设和商用的即将展开，车联网有望迎来加速发展的新阶段。车联网行业市场规模将在未来几年快速增长，行业发展前景良好。车联网的发展离不开汽车电子化程度的提升，建议关注细分行业中受益于车联网发展的企业，如顺络电子、东山精密等。

充电桩是为电动汽车提供交/直流电的充电装置。交流桩通过车载充电机充电，输出功率一般为7kw，单桩制造成本仅为800-1200 元，但充电时长8-15 小时；直流桩直接为电池充电，功率在60kw 以上，满电状态仅需20-150 分钟，但单桩制造成本约5 万元，且会对电池造成损伤。

科创板重点推荐包括云计算在内的新一代信息技术领域，允许尚未盈利的企业上市的多元包容的上市条件也为初具规模的云计算公司提供了新的融资选择。另外允许亏损企业上市，传统主流的PE 估值法便不再普遍适宜，估值成了一大难点，同时科创板采用市场询价机制，对于机构而言如何准确估值便成了重中之重。

边缘计算风口来袭，边缘计算的下一发展阶段即为边缘智能。边缘计算是云计算的重要补充，边缘智能则是边缘计算、人工智能与产业的结合。边缘AI 芯片作为其发展基础就显得尤为重要。

中国数字经济发展与就业白皮书发布：2018 年我国数字经济规模达31.3 万亿元。4 月18 日下午，“2019 中国数字经济发展论坛”在京召开。中国信通院总工程师余晓晖发布《中国数字经济发展与就业白皮书（2019 年）》。

The report covers a study of the global protein supplement market and provides the detailed analysis of the market trends, future estimations, and a thorough study of the global market based on type, form, source, distribution channel, and region. By type, the market is segmented into casein, whey protein, egg protein, soy protein, and others. Based on form, the market is segmented into powder, RTD liquid and protein bars. On the basis of source, it is segmented into animal and plant. Based on distribution channel, the market is segmented into supermarkets/hypermarkets, online, chemist/drugstore, nutrition store, health food store, specialist sports store, and others. Based on region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (UK, Germany, France, Spain, Italy, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, KSA, South Africa and Rest of LAMEA). The study highlights Porter’s five forces analysis to determine the factors affecting the market growth. These factors include raw material prices, intense competition, end users, manufacturers, and suppliers. To understand the market movement, drivers, restraints, and opportunities are explained in the report.

The revenues generated through the sale of proteomics instruments, reagents, and services are considered in the scope of the current report. However, revenues associated with related technologies such as transcriptomics and genomics are not considered in the report.

Pharmacogenomics falls in the branch of precision medicine and deals with the drug response in an individual based on his/her genetic profile. It hence allows doctors to devise a tailor-made prescription for patients suffering from life-threatening diseases such as cancer, neurological, and cardiovascular disorders. Furthermore, use of pharmacogenomics-based diagnostic tests facilitates improved drug response, reduced probability of drug failure, enhanced drug efficiency, and higher survival rate in case of cancer. Pharmacogenomics majorly includes the use of bioinformatics tools and several molecular biology techniques to determine the reason for an individual patient's illness at a molecular level. Furthermore, treatment is followed with the use of required dosage to address an individual patient's illness. This report takes into consideration the revenue generated by the sales of instruments, reagents, software, solutions, services, and therapeutics used to practice pharmacogenomics.

Orthobiologics are substances that orthopedic surgeons use to improve the healing of broken bones and injured muscles, tendons, and ligaments. These products are made from substances that are naturally found in the body; and when used in higher concentrations, orthobiologic substances help speed up the healing process. Osteoarthritis (OA) of knee is a common global cause of disability. There is an increase in the number of non-operative treatment options. Orthobiologic therapy has emerged as a novel yet effective modality for early OA. The report covers profiles of key product manufacturers in the market. These include Stryker Corporation, Zimmer Biomet Holdings, Inc., Wright Medical Group, Inc., Integra LifeSciences Holdings Corporation, Arthrex, Inc. (Arthrex), Johnson and Johnson (J&J), Exactec Inc., Medline Industries, Inc., Globus Medical, Inc., and NuVasive Inc.

Europe region holds the largest market share in the plant genotyping equipment market owing to the increasing number of initiatives taken by the European Union (EU). The ever-rising demand for food and the need for genetically modified high-quality crops along with the presence of major plant biotech solution providers are expected to boost the demand for plant genotyping equipment in the European region. Europe has always been the dominant force in the food and agriculture industry with presence of top agricultural exporting countries such as Germany, Netherlands, and France.